Orexigen garners $30M in financing
San Diego-based Orexigen Therapeutics has completed a $30 million Series C private equity financing. The deal was financed by new investors MPM BioEquities and Wasatch Advisors, along with existing investors. The money will be used to support the company's clinical programs for its two lead drug candidates: Contrave, currently in Phase II/III trials, and Excalia, which is in Phase IIb. Orexigen is involved in developing therapies for the treatment of obesity.
- check out Orexigen's press release for more on the financing
Related Article:
Orexigen gets positive Phase II results.
Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets